[조사자료] 글로벌 근골격계 질환 (MSD) 치료제 시장 (2023-2032) : 진통제, DMARD, 코르티코 스테로이드, 기타

■ 영문 제목 : Musculoskeletal Disorders Drugs Market By Drug Type (Analgesics, DMARDs, Corticosteroids, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032
	■ 상품코드 : ALD23SEP123 ■ 조사/발행회사 : Allied Market Research ■ 발행일 : 2023년 4월 ■ 페이지수 : 263 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 세계

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User	USD5,730 ⇒환산￦7,735,500	견적의뢰/주문/질문
5 User	USD6,450 ⇒환산￦8,707,500	견적의뢰/주문/질문
Enterprise User	USD9,600 ⇒환산￦12,960,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

글로벌 근골격계 질환 (MSD) 치료제 시장은 2022년 834억 7,424만 달러 규모였으며 2023년부터 2032년까지 4.2%의 연평균 성장률을 보이며 2032년에는 126억 3,022만 달러에 달할 것으로 예상됩니다. 근골격계 질환(MSD)은 근육, 뼈, 관절에 영향을 미칩니다. 이러한 장애는 신체의 다양한 부위에 통증, 뻣뻣함, 부기를 유발하며 일상 활동을 수행하는 능력에 영향을 미칩니다. 근골격계 질환의 증상으로는 관절 뻣뻣함, 부기, 둔한 통증 등이 있습니다. 이러한 장애는 반복적인 동작, 어색한 자세, 장시간 앉아 있거나 서 있는 자세 등 다양한 요인으로 인해 발생할 수 있습니다. 다발성 경화증은 모든 연령대의 사람들에게 영향을 미치지만, 노인과 운동선수 및 육체노동자처럼 근골격계에 스트레스를 주는 신체 활동을 하는 사람들에게 더 흔합니다. 가장 흔한 근골격계 질환으로는 류마티스 관절염, 골다공증, 골관절염, 섬유 근육통 등이 있습니다.

근골격계 질환 (MSD) 치료제는 신체의 근육, 뼈, 관절에 영향을 미치는 질환을 치료하는 데 사용되는 약물의 일종입니다. 이러한 약물은 류마티스 관절염, 골다공증, 섬유 근육통과 같은 근골격계 질환과 관련된 통증, 염증 및 뻣뻣함을 완화하는 데 도움이 됩니다. 근골격계 약물에는 진통제, 코르티코스테로이드, 질병 조절 항류마티스 약물, 코르티코스테로이드 등 여러 종류가 있습니다.

류마티스 관절염 골다공증 및 강직성 척추염과 같은 근골격계 질환의 유병률 증가와 근골격계 질환 치료의 가용성에 대한 인식이 급증하는 것은 시장 성장에 기여하는 요인입니다. 근무 시간 연장과 신체 활동 증가와 같은 생활 방식의 변화로 인해 근골격계 질환의 발병률이 높아졌습니다. 이는 이러한 질환을 효과적으로 관리할 수 있는 약물에 대한 수요를 증가시킬 것으로 예상됩니다. 예를 들어, 호주 보건 복지 연구소에 따르면 2020년에는 5명 중 3명이 골관절염 진단을 받은 것으로 보고되었습니다. 또한 근골격계 질환에 더 취약한 노인 인구가 증가함에 따라 이러한 질환을 관리하고 시장 성장을 더욱 촉진하기 위한 약물에 대한 수요가 증가했습니다. 그러나 저개발 국가의 치료 접근성 부족은 시장 성장을 저해 할 것으로 예상됩니다.

또한 생물학적 제제 및 바이오시밀러를 포함한 근골격계 질환에 대한 신약 개발로 치료 옵션의 효능과 안전성이 향상되었습니다. 이로 인해 이러한 약물에 대한 수요가 증가했습니다. 또한 인구 사이에서 근골격계 질환에 대한 인식이 높아짐에 따라 이러한 질환에 대한 치료와 치료를받는 환자가 증가하여 시장 성장을 지원했습니다.
글로벌 근골격계 질환 (MSD) 치료제 시장은 약물 유형, 투여 경로, 유통 채널 및 지역으로 세분화됩니다. 약물 유형에 따라 시장은 진통제, DMARD, 코르티코 스테로이드 및 기타로 분류됩니다. 투여 경로에 따라 시장은 경구 및 비경 구로 나뉩니다. 유통 채널을 기준으로 시장은 병원 약국, 온라인 제공 업체, 약국 및 소매 약국으로 분류됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽 지역), 아시아 태평양(일본, 중국, 인도, 호주, 한국, 기타 아시아 태평양), 중남미/중동/아프리카(브라질, 남아프리카공화국, 사우디아라비아, 기타 중남미/중동/아프리카) 등으로 시장을 분석합니다.

글로벌 근골격계 질환 (MSD) 치료제 시장에서 활동하는 주요 주요 업체는 AbbVie Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.등이 있습니다. 시장에서 활동하는 주요 업체는 제품 포트폴리오를 확장하기위한 주요 전략으로 제품 출시 및 제품 승인을 채택했습니다. 예를 들어, 2022년 6월 암젠은 미국 식품의 약국 (FDA)이 중등도에서 중증의 활성 류마티스 관절염이있는 성인을위한 메토트렉세이트와 병용하여 리툭산의 바이오시밀러 인 RIABNI (리툭시맙-알엑스)를 승인했다고 발표했습니다.

이해관계자를 위한 주요 이점
이 보고서는 2022년부터 2032년까지 근골격계 질환 (MSD) 치료제 시장 분석의 시장 부문, 현재 동향, 추정치 및 역학에 대한 정량적 분석을 제공하여 지배적인 근골격계 질환 (MSD) 치료제 시장 기회를 식별합니다.
시장 조사는 주요 동인, 구속 및 기회와 관련된 정보와 함께 제공됩니다.
포터의 다섯 가지 경쟁 요인 분석은 이해 관계자가 이익 지향적인 비즈니스 결정을 내리고 공급 업체-구매자 네트워크를 강화할 수 있도록 구매자와 공급 업체의 힘을 강조합니다.
근골격계 질환 (MSD) 치료제 시장 세분화에 대한 심층 분석은 지배적인 시장 기회를 결정하는 데 도움이 됩니다.
각 지역의 주요 국가는 글로벌 시장에 대한 매출 기여도에 따라 매핑됩니다.
시장 플레이어 포지셔닝은 벤치마킹을 용이하게하고 시장 플레이어의 현재 위치에 대한 명확한 이해를 제공합니다.
이 보고서에는 지역 및 글로벌 근골격계 질환 (MSD) 치료제 시장 동향, 주요 업체, 시장 부문, 응용 분야 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

주요 시장 부문
약물 유형별
진통제
DMARDs
코르티코스테로이드
기타

투여 경로별
경구
비경구

유통 채널별
병원 약국
온라인 제공업체
약국 및 소매 약국

지역별
북미
미국
캐나다
멕시코
유럽
독일
프랑스
영국
이탈리아
스페인
기타 유럽 지역
아시아 태평양
일본
중국
호주
인도
한국
기타 아시아 태평양 지역
중남미/중동/아프리카
브라질
사우디 아라비아
남아프리카 공화국
기타 중동 및 아프리카 지역

주요 기업
○ AbbVie Inc.
○ Amgen Inc.
○ Eli Lilly and Company
○ F. Hoffmann-La Roche Ltd.
○ Johnson & Johnson
○ Merck & Co., Inc.
○ Novartis AG
○ Pfizer Inc.
○ Teva Pharmaceutical Industries Ltd.
○ UCB S.A.

■ 보고서 개요

CHAPTER 1 : 소개
CHAPTER 2 : 개요
CHAPTER 3 : 시장 동향
CHAPTER 4 : 근골격계 질환(MSD) 치료제 시장, 약품 유형별
CHAPTER 5 : 근골격계 질환(MSD) 치료제 시장, 투여 경로별
CHAPTER 6 : 근골격계 질환(MSD) 치료제 시장, 유통 채널별
CHAPTER 7 : 근골격계 질환(MSD) 치료제 시장, 지역별
CHAPTER 8 : 경쟁 현황
CHAPTER 9 : 기업 정보

■ 보고서 목차

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. High prevalence of musculoskeletal (MSK) disorders
3.4.1.2. Surge in geriatric population across the globe
3.4.1.3. Increase in number of pipeline drugs

3.4.2. Restraints
3.4.2.1. Lack of treatment in emerging countries

3.4.3. Opportunities
3.4.3.1. High growth potential in emerging markets

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Analgesics
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. DMARDs
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Corticosteroids
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Parenteral
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Online Providers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Drug Stores and Retail Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Type
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Type
7.2.5.1.3. Market size and forecast, by Route of Administration
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Type
7.2.5.2.3. Market size and forecast, by Route of Administration
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Type
7.2.5.3.3. Market size and forecast, by Route of Administration
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Type
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Type
7.3.5.1.3. Market size and forecast, by Route of Administration
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Type
7.3.5.2.3. Market size and forecast, by Route of Administration
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Type
7.3.5.3.3. Market size and forecast, by Route of Administration
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Type
7.3.5.4.3. Market size and forecast, by Route of Administration
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Type
7.3.5.5.3. Market size and forecast, by Route of Administration
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Type
7.3.5.6.3. Market size and forecast, by Route of Administration
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Type
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Type
7.4.5.1.3. Market size and forecast, by Route of Administration
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Type
7.4.5.2.3. Market size and forecast, by Route of Administration
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Type
7.4.5.3.3. Market size and forecast, by Route of Administration
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Type
7.4.5.4.3. Market size and forecast, by Route of Administration
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Type
7.4.5.5.3. Market size and forecast, by Route of Administration
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Type
7.4.5.6.3. Market size and forecast, by Route of Administration
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Type
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Type
7.5.5.1.3. Market size and forecast, by Route of Administration
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Type
7.5.5.2.3. Market size and forecast, by Route of Administration
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Type
7.5.5.3.3. Market size and forecast, by Route of Administration
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Type
7.5.5.4.3. Market size and forecast, by Route of Administration
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. AbbVie Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Amgen Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Eli Lilly and Company
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. F. Hoffmann-La Roche Ltd.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Johnson & Johnson
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Merck & Co., Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Novartis AG
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Pfizer Inc.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Teva Pharmaceutical Industries Ltd.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. UCB S.A.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ANALGESICS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR DMARDS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR CORTICOSTEROIDS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 07. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 08. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 10. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 18. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 19. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 20. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 22. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 23. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 25. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 26. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 27. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 28. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 29. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 31. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 32. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 33. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 35. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 36. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 37. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 38. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 39. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 41. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 42. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 44. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 45. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 54. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 55. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 57. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 58. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 62. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 63. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 64. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 71. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 72. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 73. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 75. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 76. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 77. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 87. ABBVIE INC.: KEY EXECUTIVES
TABLE 88. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 89. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 90. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 91. ABBVIE INC.: KEY STRATERGIES
TABLE 92. AMGEN INC.: KEY EXECUTIVES
TABLE 93. AMGEN INC.: COMPANY SNAPSHOT
TABLE 94. AMGEN INC.: PRODUCT SEGMENTS
TABLE 95. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 96. AMGEN INC.: KEY STRATERGIES
TABLE 97. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 98. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 99. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 100. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 101. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 102. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 103. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 104. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 105. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 106. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 107. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 108. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 109. JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 110. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 111. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 112. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 113. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 114. NOVARTIS AG: KEY EXECUTIVES
TABLE 115. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 116. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 117. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 118. NOVARTIS AG: KEY STRATERGIES
TABLE 119. PFIZER INC.: KEY EXECUTIVES
TABLE 120. PFIZER INC.: COMPANY SNAPSHOT
TABLE 121. PFIZER INC.: PRODUCT SEGMENTS
TABLE 122. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 123. PFIZER INC.: KEY STRATERGIES
TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 129. UCB S.A.: KEY EXECUTIVES
TABLE 130. UCB S.A.: COMPANY SNAPSHOT
TABLE 131. UCB S.A.: PRODUCT SEGMENTS
TABLE 132. UCB S.A.: PRODUCT PORTFOLIO

※본 조사보고서 [글로벌 근골격계 질환 (MSD) 치료제 시장 (2023-2032) : 진통제, DMARD, 코르티코 스테로이드, 기타] (코드 : ALD23SEP123) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [글로벌 근골격계 질환 (MSD) 치료제 시장 (2023-2032) : 진통제, DMARD, 코르티코 스테로이드, 기타] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

글로벌 죽상동맥경화증 치료제 시장 (2023-2032) : 항혈소판제 및 항응고제, 콜레스테롤 저하제, ACE 억제제, 기타
ALD23SEP122 / Allied Market Research / 2023년 4월 / 글로벌 죽상동맥경화증 치료제 시장은 2022년 20,608.51백만 달러에 달했으며 2032년에는 27,711.92백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 3%의 연평균 성장률을 보일 것으로 전망됩니다. 죽상동맥경화증은 플라크가 쌓여 동맥 벽이 딱딱해져 정맥이 좁아지는...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 죽상동맥경화증 치료제 시장, 약제 유형별 CHAPTER 5 : 죽상동맥경화증 치료제 시장, 투여 경로별 CHAPTER 6 : 죽상동맥경화증 치료제 시장, 유통채널별 CHAPTER 7 : 죽상동맥경화증 치료제 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER 9...

글로벌 항비만제 시장 (2023-2032) : 처방약, 일반 의약품
ALD23SEP113 / Allied Market Research / 2023년 4월 / 글로벌 항비만제 시장은 2022년 1,605.36백만 달러 규모였으며, 2023년부터 2032년까지 10.7%의 연평균 성장률을 보이며 2032년에는 4,439.34백만 달러에 달할 것으로 예상됩니다. 비만은 건강에 부정적인 영향을 미칠 정도로 체지방이 과도하게 축적된 의학적 상태입니다....CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 항비만제 시장, 약품 유형별 CHAPTER 5 : 항비만제 시장, 작용 기전별 CHAPTER 6 : 항비만제 시장, 투여 경로별 CHAPTER 7 : 항비만제 시장, 유통 채널별 CHAPTER 8 : 항비만제 시장, 지역별 CHAPTER 9 :...

글로벌 림프종 치료제 시장 (2023-2032) : 호지킨 림프종, 비호지킨 림프종
ALD23SEP105 / Allied Market Research / 2023년 4월 / 세계의 림프종 치료제 시장은 2022년 156억 9,145만 달러로 평가되며 2023년부터 2032년까지 8.4%의 연평균 성장률을 보이며 2032년에는 352억 7,450만 달러에 달할 것으로 예상됩니다. 림프종은 감염 및 기타 질병과 싸우는 데 도움이...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 림프종 치료제 시장, 질병 유형별 CHAPTER 5 : 림프종 치료제 시장, 치료 유형별 CHAPTER 6 : 림프종 치료제 시장, 투여 경로별 CHAPTER 7 : 림프종 치료제 시장, 유통 채널별 CHAPTER 8 : 림프종 치료제...

글로벌 의약품 약물 전달 시장 (2023-2032) : 경구 약물 전달, 비강 약물 전달, 안구 약물 전달, 국소 약물 전달, 기타
ALD23SEP156 / Allied Market Research / 2023년 6월 / 글로벌 의약품 약물 전달 시장은 2022년에 14억 9,872만 달러로 평가되었으며 2023년부터 2032년까지 4.4%의 연평균 성장률을 보이며 2032년에는 2조 3,727억 달러에 달할 것으로 예상됩니다. 약물 전달은 원하는 치료 효과를 얻기 위해...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 의약품 약물 전달 시장, 투여 경로별 CHAPTER 5 : 의약품 약물 전달 시장, 용도별 CHAPTER 6 : 의약품 약물 전달 시장, 지역별 CHAPTER 7 : 경쟁 현황 CHAPTER 8 : 기업 정보...

글로벌 제네릭 의약품 시장 (2023-2032) : 심혈관, 감염, 암, 당뇨병, 기타
ALD23SEP154 / Allied Market Research / 2023년 6월 / 글로벌 제네릭 의약품 시장은 2022년에 385,320,00백만 달러로 평가되었으며 2032년에는 835,706,50백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 8.1%의 연평균 성장률을 보일 것으로 전망됩니다.제네릭 의약품은 용량 형태, 효능, 투여 방식, 품질, 성능...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 제네릭 의약품 시장, 치료 용도별 CHAPTER 5 : 제네릭 의약품 시장, 투여 경로별 CHAPTER 6 : 제네릭 의약품 시장, 유통 채널별 CHAPTER 7 : 제네릭 의약품 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER...